ResMed
(NYSE: RMD)
announced that it’s implementing a new operating model to accelerate long-term growth.
San Diego-based ResMed’s operational shift follows a recent restructuring effort that included a 5% workforce reduction. The new operating model introduces dedicated leadership in product, revenue and marketing to the company’s executive team. It includes a series of executive moves within the company’s leadership team.
Justin Leong, previously ResMed’s president for Asia and Latin America, takes over as the new chief product officer. The company selected its president in Germany, Katrin Pucknat, as its chief marketing officer. Mike Fliss, previously VP of North America sales, assumes the post of chief revenue officer.
These moves aim to increase the velocity of product development and sharpen customer and brand focus, according to a news release. The sleep respiratory technology developer said it wants to accelerate profitable growth, drive greater value and improve care.
“ResMed is the undisputed leader in digital health for respiratory medicine and residential care, and we aspire to make ourselves even more product-led, customer-centric, and brand-enhanced,” said Mick Farrell, ResMed CEO. “Today, we are making bold changes to ensure these capabilities are directly represented in our executive leadership team. We will measure the success of our new operating model through increased product velocity, increased vigilance on long-term profitable revenue delivery, and increased brand engagement with stakeholders.”
The makeup of the new ResMed operating model
In addition to the new appointments, the ResMed model’s executive team includes five more leaders. Bobby Ghoshal (CCO for SaaS) Brett Sandercock (CFO) Mike Rider (chief legal officer), Vered Keisar (chief people officer) and Hemanth Reddy (chief strategy officer) comprise that team.
Jim Ellis (chief compliance officer), Todd Friedman (chief information security officer), Amy Wakeham (chief investor relations officer), Carlos Nunez (chief medical officer), Dawn Haake (chief quality & regulatory officer) and Andrew Price (chief supply chain officer) make up the extended CEO operations team. They report directly to Farrell.
ResMed also announced that Rob Douglas, president and COO, plans to retire on Jan. 1, 2024. His retirement includes an immediate transition to a new role as special advisor to the CEO. Douglas intends to remain in a consulting role through Dec. 31, 2024.
The company also plans for Lucile Blaise to transition to a new role as SVP, strategy & business development. Blaise currently serves as president of sleep and respiratory care.
ResMed also shifted its digital health technology product organization’s structure. The company says this organization now reports to Leong, with current CTO Urvashi Tyagi transitioning to a new role. ResMed named Tyagi a special advisor to the chief product officer through Jan. 1, 2024. Tyagi will remain in a consulting role through Dec. 31, 2024.
“I’m more excited than ever about ResMed’s future, the changes we’ve made position us well to accelerate profitable growth for the benefit of all stakeholders,” Farrell said.
